Brief: Heidelberg Pharma H1 Revenues At EUR 3.1 Mln
July 9 (Reuters) - HEIDELBERG PHARMA AG HPHA.DE :
* H1 SALES REVENUE AND INCOME TOTALING EUR 3.8 MILLION
* H1 REVENUES IN AMOUNT OF EUR 3.1 MILLION (PREVIOUS YEAR:
EUR 3.8
MILLION)
* NET LOSS FOR FIRST SIX MONTHS OF 2020 FROM EUR 4.3 MILLION
IN
PREVIOUS YEAR TO EUR 9.4 MILLION
* CONFIRMS ITS GUIDANCE FOR CURRENT FISCAL YEAR PROVIDED ON
19
MARCH 2020.
* H1 OTHER INCOME OF EUR 0.7 MILLION WAS HIGHER THAN
PREVIOUS
YEAR'S FIGURE OF EUR 0.3 MILLION
Source text for Eikon: ID:nEQ2z3CqVa
Further company coverage: HPHA.DE
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;;))
Recent news on Heidelberg Pharma AG
See all newsBrief: Heidelberg Pharma And Huadong Medicine Receive Nmpa Approval For Hdp-101 Trial In China
Germany's Heidelberg Pharma H1 sales revenue surges, driven by milestone payments
Brief: Heidelberg Pharma Says Co. And Healthcare Royalty Announce Amendment To Existing Royalty Agreement
Brief: Redhill Biopharma Secures Allowance Of Key Chinese Patent Application For Proprietary COVID-19 Treatment, RHB-107
Brief: Heidelberg Pharma Amends Royalty Financing With Healthcare Royalty